Emerging data suggest Retatrutide , a dual agonist targeting both the gut-brain axis and another hormone, could represent a significant advancement for obesity loss . Early human investigations have indicated considerable losses in abdominal tissue, possibly surpassing current weight-loss medications . However , more study is needed to thoroughly a